Investigating cancer treatment effects during pregnancy on mothers and children
Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring
This study looks at how cancer treatments during pregnancy affect mothers and their children in the long run.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University Hospital, Gasthuisberg Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 33 sites (Camden, New Jersey and 32 other locations) |
| Trial ID | NCT00330447 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the outcomes for mothers diagnosed with cancer during pregnancy and the long-term effects on their children who were exposed to cancer treatments such as chemotherapy and radiotherapy. It includes collecting maternal blood samples, umbilical cord blood, and biopsies to evaluate fetal growth and maternal health. Additionally, the study will measure maternal and paternal anxiety related to the cancer diagnosis and conduct long-term follow-ups on the children to monitor their neurological and cardiological development. The study is structured in two parts, focusing on both maternal outcomes and child development.
Who should consider this trial
Good fit: Ideal candidates include premenopausal women over 18 years old with histologically proven cancer diagnosed during pregnancy or within five years post-pregnancy.
Not a fit: Patients with significant mental disabilities that prevent informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the safety and outcomes of cancer treatments during pregnancy, potentially guiding future clinical practices.
How similar studies have performed: While there have been studies on cancer treatment during pregnancy, this specific approach focusing on long-term outcomes for both mothers and children is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Patients do not need to participate in both; however, preferentially both study parts should be performed. \*\*\*\*\*\*\*\*\*\*\*\*\*\*Part I: Pregnancy, delivery and maternal health\*\*\*\*\*\*\*\*\*\*\*\*\*\* Patients must meet the following inclusion criteria: * Histologically proven cancer in association with a pregnancy (during pregnancy or cancer dagnosis within 5 years after pregnancy) * \> 18 years of age, premenopausal * Patients who have given their signed and written informed consent to participate in the trial after fully understanding the implication of the protocol * Women receiving any cytotoxic drug or radiation therapy during pregnancy are allowed for the assessment of the maternal and fetal outcome (Part II). Exclusion Criteria: * Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent \*\*\*\*\*\*\*\*\*\*\*\*\*\*Part II: Follow-up of children\*\*\*\*\*\*\*\*\*\*\*\*\*\* Inclusion Criteria: \- Children that were prenatally exposed to cancer of cancer treament. Informed Consent is asked from parents. From the age of 12 years, informed assent is additionally asked from the child. After the age of 18 years, informed consent is solely asked of the offspring. Exclusion Criteria: * Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent
Where this trial is running
Camden, New Jersey and 32 other locations
- Cooper University Hospital (2015-ongoing) — Camden, New Jersey, United States (Recruiting)
- Instituto Alexander Fleming — Buenos Aires, Argentina (Withdrawn)
- Universitätsklinik für Frauenheilkunde und Geburtshilfe (retrospective 2016-2018) — Graz, Austria (Terminated)
- UCL Brussels (2013-ongoing) — Brussels, Belgium (Recruiting)
- UZ Gasthuisberg, Katholieke Universiteit Leuven (2004-ongoing) — Leuven, Belgium (Recruiting)
- University Hospital Ostrava (2018-ongoing) — Ostrava, Czechia (Recruiting)
- 3rd medical faculty of Charles University (2010-ongoing) — Prague, Czechia (Recruiting)
- Copenhagen University Hospital (2015-ongoing) — Copenhagen, Denmark (Recruiting)
- Hopital Bichat-Claude-Bernard (retrospective until 2018) — Paris, France (Terminated)
- Universitätsklinik Freiburg (retrospective until 2018) — Freiburg im Breisgau, Germany (Terminated)
- Euroclinic Hospital (2016-ongoing) — Athens, Greece (Recruiting)
- Hellenic Anticancer-Oncological Hospital of Athens (retrospective 2015-2018) — Athens, Greece (Terminated)
- Ioannina University Hospital (retrosepctive 2015-2018) — Ioannina, Greece (Terminated)
- Hippokration Hospital (retrospective 2015-2018) — Thessaloniki, Greece (Terminated)
- European Institute of Oncology (2010-ongoing) — Milan, Italy (Recruiting)
- Fondazione IRCCS Ca'Granda Ospedale Maggiore (2012-ongoing) — Milan, Italy (Recruiting)
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano (2017-ongoing) — Milan, Italy (Recruiting)
- San Raffaele Hospital (2017-ongoing) — Milan, Italy (Recruiting)
- CIttà della Salute e della Scienza di Torino (2015-ongoing) — Torino, Italy (Recruiting)
- Regional Hospital of High Specialty of Ixtapaluca (2018-ongoing) — Ixtapaluca, Mexico (Recruiting)
- Erasmus Medical Center (2014-ongoing) — Rotterdam, Netherlands (Recruiting)
- Haukeland University Hospital (2017-ongoing) — Bergen, Norway (Recruiting)
- Medyczne Macierzynstwo (retrospective 2010-2018) — Krakow, Poland (Terminated)
- University Hospital Krakow (2018-ongoing) — Krakow, Poland (Recruiting)
- Pozanan University of Medical Sciences (2017-ongoing) — Poznan, Poland (Recruiting)
- Hospital de Vila Franca de Xira (2017-ongoing) — Vila Franca de Xira, Portugal (Recruiting)
- N.N.Blokchin National Medical Research Center of Oncology (2013-2018 retrospective; 2018-ongoing prospective) — Moscow, Russia (Recruiting)
- Research Center for Obstetrics, Gynecology and Perinatology (2014-ongoing) — Moscow, Russia (Recruiting)
- Almazov National Medical Research Center (2018-ongoing) — Saint Petersburg, Russia (Recruiting)
- Karolinska University Hospital (2017-ongoing) — Stockholm, Sweden (Recruiting)
- F.Hached University Teaching Hospital (retrospective 2016-2018) — Sousse, Tunisia (Terminated)
- Trakya University Faculty of Medicine (retrospective 2015-2018) — Edirne, Turkey (Türkiye) (Terminated)
- Grigoriev Institute for medical Radiology (retrospective until 2018) — Kharkiv, Ukraine (Terminated)
Study contacts
- Principal investigator: Amant Frederic, MD PhD — KULeuven, Belgium
- Study coordinator: Ayaka Wakatsuki
- Email: ayaka.wakatsuki@uzleuven.be
- Phone: +32 16 34 41 69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.